Compare Inovio Pharmaceuticals Inc (INO) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs M&T Bank Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.1 (market cap $112.19M), while M&T Bank Corporation trades at $216.78 (market cap $31.42B). The key difference: M&T Bank Corporation is far larger — about 280.1× Inovio Pharmaceuticals Inc's market cap, and M&T Bank Corporation pays a 2.76% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and M&T Bank Corporation for 100 Days on average.
| INO | MTB | |
|---|---|---|
Market Cap | $112.19M | $31.42B |
Volume | 3,201,278 | 1,438,219 |
Sector | Health | Financials |
52-Week High | $2.65 | $254.09 |
52-Week Low | $0.66 | $178.63 |
Typical Hold Time | 43 Days | 100 Days |
Enterprise Value | $83.51M | $47.77B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
M&T Bank (MTB) trades at $216.60, down 0.98% with a bearish technical outlook. The stock shows strong fundamentals with a P/E of 11.52 and net income margin of 30.85%, supported by three consecutive quarterly earnings beats. Recent news highlights dividend strength and branch expansion, while cash flow trends show operational stability despite negative net cash flow in 2025.
MTB presents a value opportunity with attractive valuation metrics and consistent profitability, though technical weakness and declining cash flow warrant caution. Analyst consensus targets $258.92 (19.5% upside) with 31% buy ratings, but bearish technical signals and rising debt levels pose near-term risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
